Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Early Warning Systems, Risk of Early Clinical Deterioration

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03912701
Recruitment Status : Recruiting
First Posted : April 11, 2019
Last Update Posted : July 17, 2019
Sponsor:
Information provided by (Responsible Party):
ILKE KUPELI, Erzincan University

Brief Summary:
Primary purpose of the study was to evaluate the relationship between "NEWS" and "VIEWS" scores of patients who were screened retrospectively, early clinical deterioration, return to intensive care and morbidity / mortality.

Condition or disease Intervention/treatment
Early Clinical Deterioration Diagnostic Test: Vitalpac early warning score (VIEWS)

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Case-Control
Time Perspective: Retrospective
Official Title: If Early Warning Systems Were Used, Could the Risk of Early Clinical Deterioration be Predicted and Re-admission to Intensive Care Could be Prevented
Estimated Study Start Date : August 1, 2019
Estimated Primary Completion Date : November 1, 2019
Estimated Study Completion Date : November 15, 2019

Intervention Details:
  • Diagnostic Test: Vitalpac early warning score (VIEWS)
    The Vitalpac early warning score (ViEWS) is an early warning system aimed primarily at prediction of the first 24-hour mortality in emergency patients and has not been used to assess intensive care unit discharge.


Primary Outcome Measures :
  1. Number of patients who were taken back to intensive care unit due to early clinical deterioration [ Time Frame: six month ]
    Number of patients who were taken back to intensive care unit due to early clinical deterioration



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients over the age of 18 and discharged and admitted to intensive care in the first 24 hours
Criteria

Inclusion Criteria:

  • over 18 years
  • patients who were taken back to the intensive care unit in the first 24 hours

Exclusion Criteria:

  • under 18 years old,
  • patients undergoing postoperative intensive care,
  • pregnant women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03912701


Contacts
Layout table for location contacts
Contact: ilke kupeli +905555485632 ilkeser2004@gmail.com

Locations
Layout table for location information
Turkey
Erzincan University Recruiting
Erzincan, Turkey, 24100
Contact: ufuk kuyrukluyıldız    +904462122222    drufuk2001@gmail.com   
Principal Investigator: ilke kupeli         
Sponsors and Collaborators
Erzincan University

Publications of Results:
Other Publications:
Layout table for additonal information
Responsible Party: ILKE KUPELI, assist. prof., Erzincan University
ClinicalTrials.gov Identifier: NCT03912701     History of Changes
Other Study ID Numbers: EBYU 3
First Posted: April 11, 2019    Key Record Dates
Last Update Posted: July 17, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Clinical Deterioration
Disease Progression
Disease Attributes
Pathologic Processes